Consumer Insights
Uncover trends and behaviors shaping consumer choices today
Procurement Insights
Optimize your sourcing strategy with key market data
Industry Stats
Stay ahead with the latest trends and market analysis.
The hereditary angioedema market was valued at USD 3.50 Billion in 2023, driven by the rising cases of hereditary angioedema (HAE) across 8 major markets. The market is anticipated to grow at a CAGR of 7.40% during the forecast period of 2024-2032, with the values likely to reach USD 6.65 Billion by 2032.
Base Year
Historical Year
Forecast Year
Hereditary angioedema is a disorder in which the patient experiences recurrent episodes of severe swelling in various body parts such as limbs, face, intestinal tract, and airway. Episodes that affect the intestinal tract may cause severe abdominal pain, nausea, and vomiting. Further, a swollen airway can restrict breathing and lead to life-threatening obstruction of the airway. It is also common for the patient with this condition to develop a non-itchy rash called erythema marginatum during an attack.
FDA Approvals Contributing to Increased Treatment Options and Cost Efficiency
The market growth can be attributed to the rising research and development activities by the researchers backed by key market players and governments. The rise in these clinical studies is significantly contributing to the increase in regulatory applications and approvals, leading to market development. For instance, in June 2024, Alembic Pharmaceuticals Ltd announced that they received the final approval from the United States health regulator for their generic Icatibant injection indicated for the treatment of acute attacks of hereditary angioedema in adults. The FDA approval is poised to bring a new and effective treatment option into the market, potentially solidifying the presence of Alembic Pharmaceuticals Ltd in the market while contributing to market growth.
Rising Collaborations to Expand Accessibility for Medications in Underserved Areas
The market players are increasing efforts to expand their market presence by attempting to serve more regions other than their primary hubs. Market expansion plays a crucial role in increasing the availability of the treatment in other regions and bridging the gaps of unmet need for appropriate treatments. For instance, in June 2024, Otsuka Pharmaceutical Co., Ltd. (Otsuka) announced the expansion of the licensing agreement for hereditary angioedema (HAE) drug candidate donidalorsen (genetic name) with Ionis Pharmaceuticals, Inc. (Ionis) to widen its development and commercialisation area to the Asia-Pacific region, including Japan. Otsuka has further planned to submit applications for regulatory approval of donidalorsen in Europe and the Asia-Pacific region. The company plans to apply for regulatory approval and exclusively commercialise the product in Asian-Pacific markets. The collaboration between companies is projected to stimulate market growth by delivering donidalorsen to patients across Asia Pacific and Europe to address the unmet medical needs of patients with HAE.
The market is witnessing several trends and developments to improve the current scenario. Some of the notable trends are as follows:
The market report offers a detailed analysis of the market based on the following segments:
Market Breakup by Drug Class
Market Breakup by Route of Administration
Market Breakup by End User
Market Breakup by Region
Segmentation Based on Drug Class to Witness Substantial Growth
The market report offers insights into several drug classes, namely, C1 esterase inhibitors, selective bradykinin B2 receptor antagonists, Kallikrein inhibitors and others. Out of these, the C1 Esterase inhibitor drug class dominates the market share due to its established efficacy in both acute and prophylactic treatment. It reduces the frequency and severity of HAE attacks by targeting the root cause which is C1 inhibitor deficiency. It is also available in various formulations (plasma-derived and recombinant), C1 esterase inhibitors are backed by several research, and a long track record of safety and effectiveness.
Subcutaneous Administration Leads Segmentation by Route of Administration
The subcutaneous route of administration leads the market share due to its convenience, improved patient compliance, and effectiveness in delivering therapies. Unlike intravenous administration, subcutaneous treatments can often be self-administered at home, reducing healthcare costs and enhancing patient comfort. This has contributed to the rise in preference for this administration method for long-term prophylactic treatments.
Based on region, the market is segmented into the United States, EU-4 (Germany, France, Italy, Spain), the United Kingdom Japan and India. The regional market is dominated by the United States due to the presence of a well-established healthcare infrastructure and high awareness of the condition. The market dominance can also be attributed to the availability of advanced therapies, strong investment in research and development, and the presence of major pharmaceutical companies, bolstering the region’s leadership. The presence of a large patient pool and favourable reimbursement policies that enable individuals to access expensive treatments, resulting in increased diagnoses, propels market growth.
The key features of the market report comprise patent analysis, clinical trial analysis, grants analysis, funding and investment analysis and strategic initiatives by the leading players. The major companies in the market are as follows:
Takeda Pharmaceutical is a global leader based in Japan. The company has a significant presence in the HAE market, primarily through its Firazyr, which is commonly used for the treatment of acute HAE attacks in adults. Takeda also offers Takhzyro, a preventive treatment for HAE, enhancing its portfolio in hereditary angioedema management.
CSL Behring is a global biotechnology leader that provides a range of therapies for rare and serious diseases,...
Pharvaris is a clinical-stage biopharmaceutical company focused on bringing oral therapy to patients suffering...
BioCryst Pharmaceuticals specialises in the development and marketing of novel, oral, small-molecule medicines...
Other key players in the market include Ionis Pharmaceuticals Inc., KalVista Pharmaceuticals Inc., Sanofi S.A., BioMarin Pharmaceutical Inc., Adverum Biotechnologies Inc., and Novartis AG., among others.
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
REPORT FEATURES | DETAILS |
Base Year | 2023 |
Historical Period | 2017-2023 |
Forecast Period | 2024-2032 |
Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
Breakup by Drug Class |
|
Breakup by Route of Administration |
|
Breakup by End User |
|
Breakup by Region |
|
Market Dynamics |
|
Supplier Landscape |
|
Companies Covered |
|
Purchase Full Report
Datasheet
Single User License
One User
Five User License
Five Users
Corporate License
Unlimited Users
How To Order
Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
United States (Head Office)
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Australia
63 Fiona Drive, Tamworth, NSW
+61 448 06 17 27
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-858-608-1494
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City,1226.
+63 287899028, +63 967 048 3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84865399124